Promising combo tackles tough lung cancer
Disease control
Completed
This study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or I…
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC